Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all news
11.22.2011

Wexler Wallace LLP Files Class Action on Behalf of Hospira, Inc. Investors

On November 21, 2011, Wexler Wallace, with co-counsel Robbins Geller Rudman & Dowd LLP, filed a class action in the United States District Court for the Northern District of Illinois on behalf of purchasers of common stock in Hospira, Inc., (“Hospira”) (NYSE: HSP) between March 24, 2009, and October 17, 2011 (“Class Period”).

Hospira is a global specialty pharmaceutical and medication delivery company.  Its products are used by hospital and alternative site providers, such as clinics, home healthcare providers and long-term care facilities.  The complaint alleges that throughout the Class Period, Hospira issued materially false and misleading statements regarding its operations and financial results.  Specific allegations include Hospira’s failure to disclose that: (i) it suffered from extensive quality control issues throughout the Class Period, which undermined both the viability of and the supposed financial savings that would be generated by Project Fuel, a Company program designed to optimize Hospira’s operations and increase shareholder value; (ii) Hospira was unable to remedy problems identified in FDA Warning Letters related to Hospira’s infusion pumps, quality control deficiencies, and manufacturing weaknesses; (iii) Hospira’s revenue guidance for 2010 and 2011 was misstated and lacked a reasonable basis when made; and (iv) as a result, Hospira’s statements regarding its financial performance and expected earnings were false and lacked a reasonable basis when made.

If you purchased common stock in Hospira between March 24, 2009, and October 17, 2011, or would like more information about this case, you may contact us by completing our online form or by calling 312-346-2222.

To view a copy of the Complaint, please click here.

Share

  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP